Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system

Eugene Jeong, Scott D. Nelson, Yu Su, Bradley Malin, Lang Li, You ChenFrontiers in Pharmacology 2022 · DOI

TL;DR

This study leverages the FDA's Adverse Event Reporting System (FAERS) to identify potential drug-drug interactions (DDIs) between COVID-19 treatments and common co-medications. By employing advanced statistical methods and validating findings with existing databases, the research uncovers numerous novel DDIs and highlights age and gender-specific risks, underscoring the need for further investigation into these interactions.

What Problem Does This Paper Address?

The COVID-19 pandemic has led to the widespread use of various therapeutic agents, including repurposed drugs, for treatment. Patients with COVID-19 often have underlying medical conditions, making them susceptible to polypharmacy (the use of multiple medications). This increased medication burden significantly raises the risk of drug-drug interactions (DDIs), which can lead to unexpected and potentially severe adverse events (AEs). While clinical trials assess drug safety, they are limited in scope and duration, often failing to capture rare or long-term DDIs that emerge in real-world, diverse patient populations. Therefore, there's a critical need for robust post-market surveillance systems to identify and characterize these DDIs, especially for novel or repurposed COVID-19 therapies.

Methods

The researchers employed a discovery-driven approach using multivariate logistic regression to analyze the FAERS database. Key to their methodology was the use of Firth logistic regression, a penalized likelihood method chosen to address potential issues with small sample sizes and separation in logistic regression models, which can lead to imprecise and biased estimates.

To quantify DDIs, they assessed interactions on both an additive scale (using Relative Excess Risk due to Interaction - RERI) and a multiplicative scale (using the odds ratio interaction term, $\beta_3$). The RERI was approximated using odds ratios derived from the logistic regression model. DDIs were considered significant if there was evidence of interaction on at least one scale.

To validate their findings and assess the likelihood of these interactions being coincidental, they conducted a Monte Carlo simulation with 1,000 replicates. They also compared their identified DDIs against the Liverpool database, a known resource for COVID-19 drug interactions. Furthermore, they specifically investigated age and gender disparities in DDI signals.

Datasets

The primary dataset used in this study was the FDA Adverse Event Reporting System (FAERS) database. Specifically, they analyzed data from January 2020 to September 2021, encompassing demographic, drug, indication, and outcome files.

They also utilized the Liverpool database (derived from Covid19-druginteraction.org) for comparison and validation of identified DDIs.

Key Insights and Ideas

  • FAERS as a powerful DDI discovery engine: The study demonstrates that FAERS, despite its limitations, can be a valuable source for generating hypotheses about novel DDIs, especially in the context of rapidly evolving treatment landscapes like COVID-19.
  • Beyond known interactions: A significant portion of the identified DDIs were not documented in the Liverpool database, highlighting the potential for discovering previously unrecognized safety signals.
  • Age and gender matter: The analysis revealed distinct patterns of DDIs based on age and gender, suggesting that these demographic factors can influence drug interaction risks. This granular insight is crucial for personalized medicine.
  • Statistical rigor for signal detection: The use of Firth logistic regression and Monte Carlo simulations adds a layer of statistical robustness to the DDI signal detection, helping to distinguish true signals from random noise.

Key Results

  • The study analyzed 18,589 COVID-19 adverse event reports.
  • After applying a minimal guideline criterion of 5 events per variable (EPV), 10,195 COVID-19 drug-co-medication-AE combinations were considered.
  • A total of 424 statistically significant DDI signals were identified, involving 176 unique drug-drug pairs. These pairs comprised 13 COVID-19 drugs and 60 co-medications.
  • Of the 176 drug-drug pairs, only 20 were found in the Liverpool database, indicating a high proportion of novel findings.
  • The Monte Carlo simulation yielded an empirical p-value < 0.001, strongly suggesting that the detected DDIs are unlikely to be coincidental.
  • Remdesivir was found to interact with the largest number of concomitant drugs (41).
  • Hydroxychloroquine was associated with the highest number of unique AEs (39).
  • 323 gender-specific and 254 age-specific DDI signals were identified.

Limitations and Future Work

  • Causality: FAERS data is based on spontaneous reports, and while the study used statistical methods to identify associations, it cannot definitively prove causality. Adverse events may be due to underlying conditions, other unrecorded medications, or other factors.
  • Data Completeness and Quality: The FAERS database can contain duplicate reports, incomplete information, and reporting bias (under-reporting). While data cleaning and imputation were performed, these limitations persist.
  • Confounding Factors: While age, gender, and number of drug exposures were adjusted for, other potential confounders like smoking habits, general health status, and specific patient medical histories were not fully accounted for.
  • Drug-Disease Interactions: The study acknowledges the possibility of drug-disease interactions, where a patient's underlying condition (e.g., renal impairment) might contribute to an adverse event rather than a direct DDI.

The authors suggest that the identified DDIs, particularly those not found in existing databases, warrant further investigation through pharmacoepidemiological and pharmacological studies to confirm their clinical significance and elucidate their mechanisms. Future work could also focus on improving data quality and imputation methods for FAERS.

Summary updated

Abstract

<b>Background:</b> COVID-19 patients with underlying medical conditions are vulnerable to drug-drug interactions (DDI) due to the use of multiple medications. We conducted a discovery-driven data analysis to identify potential DDIs and associated adverse events (AEs) in COVID-19 patients from the FDA Adverse Event Reporting System (FAERS), a source of post-market drug safety. <b>Materials and Methods:</b> We investigated 18,589 COVID-19 AEs reported in the FAERS database between 2020 and 2021. We applied multivariate logistic regression to account for potential confounding factors, including age, gender, and the number of unique drug exposures. The significance of the DDIs was determined using both additive and multiplicative measures of interaction. We compared our findings with the Liverpool database and conducted a Monte Carlo simulation to validate the identified DDIs. <b>Results:</b> Out of 11,337 COVID-19 drug-Co-medication-AE combinations investigated, our methods identified 424 signals statistically significant, covering 176 drug-drug pairs, composed of 13 COVID-19 drugs and 60 co-medications. Out of the 176 drug-drug pairs, 20 were found to exist in the Liverpool database. The empirical <i>p</i>-value obtained based on 1,000 Monte Carlo simulations was less than 0.001. <i>Remdesivir</i> was discovered to interact with the largest number of concomitant drugs (41). <i>Hydroxychloroquine</i> was detected to be associated with most AEs (39). Furthermore, we identified 323 gender- and 254 age-specific DDI signals. <b>Conclusion:</b> The results, particularly those not found in the Liverpool database, suggest a subsequent need for further pharmacoepidemiology and/or pharmacology studies.
BibTeX
@inproceedings{jeong2022detecting,
  author = {Eugene Jeong and Scott D. Nelson and Yu Su and Bradley Malin and Lang Li and You Chen},
  title = {{Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.938552},
}
Figure